PT Pan Brothers Tbk (IDX:PBRX)
Indonesia · Delayed Price · Currency is IDR 21.00
+1.00 (5.00%)
Aug 1, 2025, 2:55 PM WIB
Verve Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
| 279.47 | 319.93 | 581.62 | 690.04 | 689.44 | 684.89 | Upgrade | |
Revenue Growth (YoY) | -50.43% | -44.99% | -15.71% | 0.09% | 0.66% | 2.98% | Upgrade |
Cost of Revenue | 364.9 | 398.61 | 525.98 | 619.85 | 612.94 | 598.96 | Upgrade |
Gross Profit | -85.43 | -78.68 | 55.64 | 70.2 | 76.5 | 85.93 | Upgrade |
Selling, General & Admin | 26.26 | 25.88 | 28.11 | 34.21 | 34.06 | 34.07 | Upgrade |
Other Operating Expenses | 3 | 3.18 | 2.66 | 1.76 | 1.41 | 1.4 | Upgrade |
Operating Expenses | 29.25 | 29.06 | 30.76 | 35.97 | 35.48 | 35.47 | Upgrade |
Operating Income | -114.68 | -107.74 | 24.87 | 34.23 | 41.03 | 50.46 | Upgrade |
Interest Expense | -5.43 | -8.08 | -26.68 | -23.1 | -18.31 | -20.03 | Upgrade |
Interest & Investment Income | 2.46 | 2.85 | 2.02 | 0.12 | 1.83 | 0.35 | Upgrade |
Currency Exchange Gain (Loss) | -2.77 | -2.84 | 1.09 | -1 | -1.11 | -0.21 | Upgrade |
Other Non Operating Income (Expenses) | -43.74 | -41.51 | -3.61 | -3.7 | -1.9 | -3.64 | Upgrade |
EBT Excluding Unusual Items | -164.16 | -157.32 | -2.3 | 6.55 | 21.53 | 26.94 | Upgrade |
Impairment of Goodwill | - | - | - | -0.27 | -0.51 | -0.91 | Upgrade |
Gain (Loss) on Sale of Investments | -293.29 | -293.29 | - | - | - | -0.02 | Upgrade |
Gain (Loss) on Sale of Assets | 0.01 | -0.01 | 0.13 | 0.06 | -0.21 | -0.06 | Upgrade |
Other Unusual Items | 101.57 | - | - | - | - | -6.34 | Upgrade |
Pretax Income | -355.88 | -450.63 | -2.17 | 6.84 | 21.09 | 25.95 | Upgrade |
Income Tax Expense | 5.31 | 5.36 | 2.17 | 4.51 | 5.68 | 6.58 | Upgrade |
Earnings From Continuing Operations | -361.19 | -455.99 | -4.34 | 2.34 | 15.4 | 19.37 | Upgrade |
Minority Interest in Earnings | 7.4 | 7.68 | 3.12 | 1.35 | 0.74 | 4.34 | Upgrade |
Net Income | -353.79 | -448.31 | -1.22 | 3.68 | 16.14 | 23.71 | Upgrade |
Net Income to Common | -353.79 | -448.31 | -1.22 | 3.68 | 16.14 | 23.71 | Upgrade |
Net Income Growth | - | - | - | -77.18% | -31.93% | 17.16% | Upgrade |
Shares Outstanding (Basic) | 21,482 | 21,482 | 21,482 | 6,478 | 6,478 | 6,478 | Upgrade |
Shares Outstanding (Diluted) | 21,482 | 21,482 | 21,482 | 6,478 | 6,478 | 6,478 | Upgrade |
Shares Change (YoY) | - | - | 231.60% | - | - | - | Upgrade |
EPS (Basic) | -0.02 | -0.02 | -0.00 | 0.00 | 0.00 | 0.00 | Upgrade |
EPS (Diluted) | -0.02 | -0.02 | -0.00 | 0.00 | 0.00 | 0.00 | Upgrade |
EPS Growth | - | - | - | -77.20% | -31.94% | 17.16% | Upgrade |
Free Cash Flow | -8.79 | -5.65 | -32.75 | 10.67 | -7.79 | -40.78 | Upgrade |
Free Cash Flow Per Share | - | - | -0.00 | 0.00 | -0.00 | -0.01 | Upgrade |
Gross Margin | -30.57% | -24.59% | 9.57% | 10.17% | 11.10% | 12.55% | Upgrade |
Operating Margin | -41.04% | -33.68% | 4.28% | 4.96% | 5.95% | 7.37% | Upgrade |
Profit Margin | -126.59% | -140.13% | -0.21% | 0.53% | 2.34% | 3.46% | Upgrade |
Free Cash Flow Margin | -3.15% | -1.76% | -5.63% | 1.55% | -1.13% | -5.95% | Upgrade |
EBITDA | -108.47 | -101.49 | 34.58 | 45.35 | 54.2 | 63.39 | Upgrade |
EBITDA Margin | -38.81% | -31.72% | 5.95% | 6.57% | 7.86% | 9.25% | Upgrade |
D&A For EBITDA | 6.21 | 6.25 | 9.71 | 11.12 | 13.17 | 12.93 | Upgrade |
EBIT | -114.68 | -107.74 | 24.87 | 34.23 | 41.03 | 50.46 | Upgrade |
EBIT Margin | -41.03% | -33.68% | 4.28% | 4.96% | 5.95% | 7.37% | Upgrade |
Effective Tax Rate | - | - | - | 65.86% | 26.95% | 25.35% | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.